The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting

Publication date

2012

Authors

Harmsze, Ankie MISNI 0000000395050870
van Werkum, Jochem W
Hackeng, Christian M
Ruven, Hendrik J T
Kelder, Johannes C
Bouman, Heleen J
Breet, Nicoline J
Ten Berg, Jurriën M
Klungel, Olaf H.ISNI 0000000390199414
de Boer, AnthoniusISNI 0000000389596105

Editors

Advisors

Supervisors

Document Type

Article
Open Access logo

License

Abstract

OBJECTIVES: To investigate the impact of genotypes on the basis of the loss-of-function variant CYP2C19*2 and the gain-of-function variant CYP2C19*17 on on-treatment platelet reactivity and on the occurrence of Thrombolysis in Myocardial Infarction (TIMI) major bleedings in 820 clopidogrel-treated patients who underwent elective coronary stenting. METHODS: On-treatment platelet reactivity was quantified using ADP-induced light transmittance aggregometry (LTA) and the VerifyNow P2Y12 assay. Postdischarge TIMI major bleedings within 1 year after enrollment were recorded. RESULTS: In total, 25 major bleedings (3.0% of the study population) were observed. Patients with the CYP2C19*1/*17 and *17/*17 diplotypes exhibited a lower magnitude of platelet reactivity as compared with patients with the CYP2C19*1/*1 diplotype (for the light transmittance aggregometry-adjusted mean difference: -5.8%, 95% confidence interval: -9.6 to -2.1, P=0.002). Patients with the *1/*17 and *17/*17 genotype had a 2.7-fold increased risk in the occurrence of major bleedings [adjusted hazard ratio: 2.7, 95% confidence interval: 1.1-7.0, P=0.039]. The diplotypes *2/*17, *1/*2, and *2/*2 exhibited higher on-treatment platelet reactivity as compared with the wild type (P<0.0001). However, this was not translated into an altered risk on major bleedings as compared with the wild type [hazard ratio: 1.3 (0.45-4.0), P=0.60]. Results have not been adjusted for multiple testing. CONCLUSION: Patients with the CYP2C19*1/*17 and *17/*17 diplotype have a lower magnitude of on-treatment platelet reactivity and are at a 2.7-fold increased risk of postdischarge TIMI major bleeding events after coronary stenting than patients with the *1/*1 genotype. The diplotypes *2/*17, *1/*2, and *2/*2 are associated with increased on-treatment platelet reactivity; however, this is not translated into a lower risk of bleeding events.

Keywords

Alleles, Angioplasty, Balloon, Coronary, Aryl Hydrocarbon Hydroxylases/genetics, Coronary Artery Disease/genetics, Cytochrome P-450 CYP2C19, Follow-Up Studies, Genotype, Hemorrhage/genetics, Humans, Platelet Activation/genetics, Platelet Aggregation/genetics, Polymorphism, Genetic

Citation

Harmsze, A M, van Werkum, J W, Hackeng, C M, Ruven, H J T, Kelder, J C, Bouman, H J, Breet, N J, Ten Berg, J M, Klungel, O H, de Boer, A & Deneer, V H M 2012, 'The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting', Pharmacogenetics and Genomics, vol. 22, no. 3, pp. 169-175. https://doi.org/10.1097/FPC.0b013e32834ff6e3